compareglp-1

A comparison studio
Independent editorial information · not individual medical advice

Commercial pages may contain paid referral links. Compare the full payment terms and licensed-care details before enrollment.

Deep Dive

The Compounded GLP-1 Market in 2026: What Survived, What Changed, What to Check

The gold-rush era ended; a smaller, more scrutinized market remains. An honest state-of-play for anyone still shopping it.

The compounded GLP-1 boom was a creature of shortage: while brand semaglutide and tirzepatide sat on FDA shortage lists, compounding pharmacies could produce copies at scale, and a massive telehealth economy grew around $150–$300 alternatives to $1,000+ brands. Then the shortages resolved, the FDA wound down mass copying, MFN pricing cut brand to $199 — and the market's entire reason for being was forced to evolve. Here's the honest 2026 state of play.

What Changed

The 2026 Buyer's Checklist

Shopping the surviving market well means asking five questions every time:

Programs Representative of the Surviving Market

SPONSORED CARE OPTION

Ivím Health

Compare treatment availability, consultation and membership charges, pharmacy fees and refill policies. Eligibility and medication choice are determined by a clinician.

Pricing, medication access, service area and plan terms must be confirmed with the provider. This is not a drug-specific checkout link.

Explore Ivím Health program ↗
Budget Survivor

GobyMeds

The lowest injectable price point we currently track.

Injectable compounded semaglutide $99/mo · tirzepatide $133/mo

  • Among the lowest injectable prices tracked
  • Direct pharmacy model
  • Flat monthly pricing

Compounded medications are not FDA-approved. They are prepared by licensed pharmacies but have not been evaluated by the FDA for safety, effectiveness, or quality.

Visit GobyMeds
Format Play — Oral

Wellorithm

One of the lowest oral entry prices in the compounded market.

Compounded oral semaglutide tablets from $147/mo · oral tirzepatide from $249/mo

  • Oral tablet format
  • Among the lowest oral prices tracked
  • Provider consult included

Compounded medications are not FDA-approved. They are prepared by licensed pharmacies but have not been evaluated by the FDA for safety, effectiveness, or quality.

The brand check, always: before any compounded purchase in 2026, price the brand route for your situation — $199 pens, $149 pills, $299 tirzepatide. If compounded doesn't beat it on your specific math (bundled total, dose behavior, or format), the FDA-approved product wins by default.
Our verdict: the compounded market of 2026 is smaller, more scrutinized, and — for careful buyers — arguably safer to navigate than its gold-rush ancestor. It earns its place only in three lanes: all-in totals below brand, flat pricing for dose-climbers, and needle-free formats brand doesn't offer. Shop those lanes with the checklist, or don't shop it at all.

Bottom Line

Compounding didn't die with the shortages; it shrank to its defensible core. Know the three lanes where it still wins, run the five-question checklist without exceptions, and let the $199 brand era do what it does best — keep everyone honest.

Last updated August 2026. Compounded medications are not FDA-approved. Regulatory conditions continue to evolve; verify current status with any program.

See the Full Comparison Grid

Every provider and channel we track — price, format, and what's included — side by side.

Compare All Providers

More Comparisons

Wegovy at $199 vs. Compounded

Safety Profiles Compared

Every Channel Ranked by Price

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. All prescription medications discussed require evaluation by a licensed healthcare provider. Always consult your doctor before starting, stopping, or changing any medication. Individual results vary.

Affiliate Disclosure: CompareGLP-1 may earn a commission when you use links on this page, at no additional cost to you. Links marked "Paid link" are sponsored. Our comparisons are editorially independent — rankings and verdicts are never sold, and we never fabricate statistics, testimonials, or reviews.